# CANTATA (NCT03428217)

> CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03428217
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Calithera Biosciences, Inc
- Conditions: Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
- Interventions: CB-839; Cabozantinib; Placebo
- Enrollment: 444
- Primary outcome: Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)

## Commentary we found

- Podcasts: 6
- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cantata-nct03428217

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03428217", "email": "<work email>"}; the inbox owner confirms by the emailed link.